ProBiotix Health Expands into Belgium via Nutrisan Partnership to Supply Patented LP LDL® Probiotic for Cardiometabolic Health

ProBiotix Accelerates European Growth Strategy with Nutrisan Partnership

ProBiotix Health plc has announced a strategic alliance aimed at accelerating its expansion into the European nutraceutical sector. The company, specialising in probiotic formulations supporting cardiometabolic health, will supply its patented LP LDL® strain to Nutrisan for integration into a new Nutrisan PRO product line. This partnership aligns with ProBiotix's strategy to collaborate with premium nutraceutical brands and distribute LP LDL® through healthcare professional channels rather than direct consumer sales.

The agreement represents a significant geographic expansion, positioning Belgium as a key new market for ProBiotix. Nutrisan will act as the primary commercial partner, managing packaging, branding, marketing, and distribution. This enables ProBiotix to leverage Nutrisan's established relationships with pharmacists, healthcare professionals, and specialists across Belgium while retaining quality control over the probiotic formulation.

Nutrisan’s Market Presence and Commitment to LP LDL® Growth

Based in Sint-Niklaas, Belgium, Nutrisan has been a prominent player in the European nutraceutical industry since 1998. The company focuses on developing, producing, and distributing high-quality natural supplements, serving specialists, general practitioners, pharmacists, and paramedics. Nutrisan's portfolio covers cardiovascular and metabolic health, immune support, cognitive health, and general wellbeing, distributed widely across Belgium and internationally.

Nutrisan has pledged substantial long-term investment to support LP LDL® in Belgium, including scientific training, facilitating connections with healthcare professionals, continuing education programs, and funding high-quality marketing and digital campaigns. Additionally, Nutrisan recently launched a webshop enabling direct purchases via social media, complementing traditional pharmacy and healthcare professional distribution channels.

Clinical Validation and Selection of LP LDL®

Nutrisan selected LP LDL® after thorough evaluation of clinically supported cardiometabolic ingredients. The probiotic strain was chosen for its differentiated profile, backed by robust peer-reviewed clinical evidence demonstrating benefits for healthy cholesterol levels and a unique mechanism of action. This rigorous selection reflects Nutrisan’s commitment to products meeting high scientific standards for healthcare professional endorsement.

LP LDL® will be offered as a single-strain probiotic in 60-capsule packs within the Nutrisan PRO range, targeting healthcare practitioners and consumers seeking evidence-based cholesterol support. The focus on clinical substantiation and distinct mechanism aligns with growing market expectations for scientifically validated nutraceuticals.

Belgium’s Cardiovascular Disease Burden and Market Potential

Belgium presents a significant market opportunity for cardiometabolic health products. Cardiovascular disease accounts for approximately 28% of deaths nationally, making it a leading cause of mortality. About half of Belgian adults have elevated cholesterol levels, a primary cardiovascular risk factor.

With an estimated 1.3 million people living with cardiovascular disease and around 123,000 new cases annually, the demand for evidence-based cholesterol management solutions is substantial. Marketing LP LDL® through healthcare professional channels leverages clinical evidence and professional endorsements to influence prescribing and recommendation patterns.

Distribution Strategy Focused on Healthcare Professionals

ProBiotix’s partnership with Nutrisan reflects a strategic focus on distribution via healthcare professionals rather than solely retail or direct-to-consumer models. Nutrisan’s established network of pharmacists, general practitioners, specialists, and paramedics across Belgium provides access to professional recommenders who can educate patients on LP LDL® and its clinical benefits. This approach supports positioning LP LDL® as a premium, science-driven solution requiring professional engagement.

Nutrisan’s investment in continuing professional education and scientific training underscores the importance of this channel. The company will facilitate introductions to healthcare professionals, deliver ongoing education, and develop communications linking gut microbiome function to cardiometabolic health. These efforts aim to build sustained market awareness and professional adoption beyond consumer advertising.

ProBiotix’s European Positioning and Growth Outlook

The Nutrisan collaboration is a strategic step in ProBiotix’s plan to expand its European presence through partnerships with premium nutraceutical brands. Belgium is identified as a growth market with favorable conditions for LP LDL® revenue expansion. The partnership model, where ProBiotix supplies the formulation and partners handle packaging and marketing, facilitates rapid market entry with reduced capital and operational demands compared to direct distribution.

CEO Steen Andersen expressed confidence in increasing Belgian market awareness of LP LDL®’s benefits, describing Nutrisan as an innovative partner aligned with ProBiotix’s vision of LP LDL® as a premium, science-led product. This collaboration may serve as a blueprint for similar European partnerships. Financial terms, revenue goals, and timelines were not disclosed.

Product Supply and Formulation Details

Under the agreement, ProBiotix will supply the finished probiotic formulation to Nutrisan, which will manage packaging, branding, and marketing for Belgian distribution. This structure allows ProBiotix to maintain control over the probiotic strain and formulation quality while leveraging Nutrisan’s local market expertise and distribution network. The product will be marketed as LP LDL® within Nutrisan’s PRO supplement line, aimed at pharmacists and healthcare professionals.

The 60-capsule pack aligns with standard European supplement formats for pharmacy and healthcare channels, reflecting commercial practicality. The announcement did not specify product launch timing, manufacturing capacity for Belgium, or exclusivity terms.

Market Context: Microbiome-Based Cardiometabolic Solutions

This partnership announcement coincides with growing scientific recognition of the gut microbiome’s role in cardiovascular and metabolic health. Both ProBiotix and Nutrisan highlight LP LDL®’s unique mechanism via the gut microbiome, positioning it as a differentiated probiotic category within the nutraceutical market. This scientific focus distinguishes LP LDL® from traditional cholesterol management products and appeals to healthcare professionals and consumers seeking evidence-based innovation.

Nutrisan CEO Jan De Backer described LP LDL® as "a new generation of probiotics" due to its unique gut microbiome mechanism and scientific validation. This messaging emphasizes scientific differentiation and mechanism of action over solely clinical efficacy claims, aligning with Nutrisan’s philosophy, "Focused on Science, driven by Nature," reflecting shared brand and market positioning.

Regulatory Compliance and Disclosure

The announcement includes a standard disclosure confirming the information was considered inside information under UK Market Abuse Regulation before public release, with directors responsible for the disclosure. This ensures compliance with regulatory requirements for simultaneous market communication of material developments.

Clinical and epidemiological data cited derive from Statista, peer-reviewed studies, and OECD sources, demonstrating efforts to substantiate health claims with credible independent evidence. In the European nutraceutical market, health benefit claims undergo strict regulatory scrutiny, making peer-reviewed clinical support essential for marketing through healthcare professional channels.